VS-6063
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Docetaxel, the standard chemotherapy for metastatic castration‐resistant prostate cancer (CRPC) also enhances the survival of…
ABSTRACT The non-receptor cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK) is known to play a key role in a variety of…
Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting…
Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis and tumor recurrence, therapeutic targeting…
AbstractPurpose
VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase and…
SummaryObjective VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK…
Malignant pleural mesothelioma (MPM) is an aggressive tumor in the lining of the lung often resulting from prior exposure to…
5521 Background: Defactinib (VS-6063) is an oral inhibitor of focal adhesion kinase (FAK). Blockade of FAK has been shown to…
BACKGROUND
We previously found focal adhesion kinase (FAK) inhibition sensitizes ovarian cancer to taxanes; however, the…